The Relationship Between HIV Pre-exposure Prophylaxis Stigma and Treatment Adherence Among Current HIV Pre-exposure Prophylaxis Users in the Southeastern US

被引:4
|
作者
Van Gerwen, Olivia T. [1 ]
Yigit, Ibrahim [2 ]
Crockett, Kaylee B. [3 ]
Turan, Bulent [4 ,5 ]
机构
[1] Univ Alabama Birmingham, Div Infect Dis, 703 19th St South,ZRB 218A, Birmingham, AL 35233 USA
[2] TED Univ, Fac Arts & Sci, Dept Psychol, Ankara, Turkey
[3] Univ Alabama Birmingham, Dept Family & Community Med, Birmingham, AL USA
[4] Koc Univ, Coll Social Sci & Humanities, Dept Psychol, Istanbul, Turkey
[5] Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA
基金
美国国家卫生研究院;
关键词
HIV pre-exposure prophylaxis; Adherence; Stigma; PrEP; TENOFOVIR DISOPROXIL FUMARATE; INTERNALIZED STIGMA; PREVENTION; MECHANISMS; INFECTION; EFFICACY; PEOPLE; SCALE; RISK; PREP;
D O I
10.1007/s10461-022-03883-3
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Despite efficacy in HIV prevention, Pre-exposure Prophylaxis (PrEP) is underutilized in the US, especially among populations at highest risk. PrEP-related stigma may play a role. We developed measures of PrEP-related stigma dimensions and PrEP adherence. We administered them to current PrEP users. We hypothesized that PrEP-related stigma would negatively impact PrEP adherence. Questionnaire measures were developed using data from previous qualitative work and existing validated HIV-related stigma measures. The resultant survey was administered to current PrEP users from two Birmingham, Alabama PrEP clinics. Plasma tenofovir disoproxil fumarate levels were collected to measure PrEP adherence. Exploratory factor analyses were performed to determine the factor structure of each PrEP-related stigma dimension (internalized, perceived, experienced, anticipated, disclosure concerns). Separate binary logistic (or linear) regressions were performed to assess associations between PrEP-related stigma dimensions and adherence (treatment adherence self-efficacy, self-reported adherence, and plasma tenofovir levels), adjusting for education, race, and time on PrEP. In 2018, 100 participants completed the survey, with 91 identifying as male and 66 as white. Only internalized stigma was associated with lower self-reported PrEP adherence. Exploratory mediation analyses suggested that the association between all stigma dimensions and self-reported PrEP adherence is mediated by PrEP adherence self-efficacy. No associations were found between any PrEP-related stigma measures and plasma tenofovir levels. Internalized PrEP stigma may reduce PrEP adherence, possibly by reducing PrEP adherence self-efficacy among experienced PrEP users. Further investigation of how stigma dimensions affect PrEP adherence in populations at risk for HIV may shed light on drivers of PrEP underutilization.
引用
收藏
页码:1478 / 1485
页数:8
相关论文
共 50 条
  • [31] Adherence to Pre-Exposure Prophylaxis for HIV Prevention in a Clinical Setting
    Montgomery, Madeline C.
    Oldenburg, Catherine E.
    Nunn, Amy S.
    Mena, Leandro
    Anderson, Peter
    Liegler, Teri
    Mayer, Kenneth H.
    Patel, Rupa
    Almonte, Alexi
    Chan, Philip A.
    PLOS ONE, 2016, 11 (06):
  • [32] Reported Side Effects and Adherence of Daily HIV Pre-Exposure Prophylaxis Users in Ontario, Canada: An Analysis of the Ontario Pre-Exposure Prophylaxis Cohort Study
    Rudd, Monica
    McGarrity, Matthew
    Lisk, Ryan
    MacPherson, Paul
    Knox, David
    Woodward, Kevin
    Reinhart, Jeff
    MacLeod, John
    Bogoch, Isaac I.
    Clatworthy, Deanna
    Biondi, Mia J.
    Sullivan, Sean
    Li, Alan
    Durrant, Garfield
    Schonbe, Andrew
    Ongoiba, Fanta
    Burchell, Ann N.
    Tan, Darrell H. S.
    AIDS PATIENT CARE AND STDS, 2024, 38 (09) : 382 - 392
  • [33] Preparing for pre-exposure prophylaxis: perceptions and readiness of Canadian pharmacists for the implementation of HIV pre-exposure prophylaxis
    Yoong, Deborah
    Naccarato, Mark
    Sharma, Malika
    Wilton, James
    Senn, Heather
    Tan, Darrell H. S.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2016, 27 (08) : 608 - 616
  • [34] Pharmacists as providers of HIV pre-exposure prophylaxis
    Christine Bruno
    Parya Saberi
    International Journal of Clinical Pharmacy, 2012, 34 : 803 - 806
  • [35] Pre-exposure prophylaxis as HIV prevention in the UK
    Brady, Michael
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2016, 7 (03) : 150 - 152
  • [36] HIV moments and pre-exposure prophylaxis Reply
    Dunn, David T.
    Gafos, Mitzy
    White, Ellen
    McCormack, Sheena
    LANCET, 2016, 387 (10027): : 1508 - 1508
  • [37] HIV pre-exposure prophylaxis: effective and underused
    Hempel, Amanda
    Biondi, Mia J.
    Baril, Jean-Guy
    Tan, Darrell H. S.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2022, 194 (45) : E1544 - E1550
  • [38] Pharmacists as providers of HIV pre-exposure prophylaxis
    Bruno, Christine
    Saberi, Parya
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2012, 34 (06) : 803 - 806
  • [39] HIV prevention using pre-exposure prophylaxis
    Daou, S.
    Calmy, A.
    REVUE DE MEDECINE INTERNE, 2011, 32 (11): : 658 - 662
  • [40] Oral pre-exposure prophylaxis for HIV prevention
    Garcia-Lerma, J. Gerardo
    Paxton, Lynn
    Kilmarx, Peter H.
    Heneine, Walid
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2010, 31 (02) : 74 - 81